PMC:7784786 / 6612-6811 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"235","span":{"begin":8,"end":18},"obj":"Chemical"},{"id":"239","span":{"begin":183,"end":199},"obj":"Disease"}],"attributes":[{"id":"A235","pred":"tao:has_database_id","subj":"235","obj":"MESH:C000597346"},{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"MESH:D010996"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":") After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. The minor pleural effusion"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":183,"end":199},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002202"}],"text":") After itolizumab (48 h): radiological improvement with decreased diffuse infiltrate and radio-opacity at the top of both lungs and in both lung bases, in less proportion. The minor pleural effusion"}